

#1

03CO



PATENT  
Customer No. 22,852  
Attorney Docket No. 3495.0050-16

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
Marc ALIZON et al. ) Group Art Unit: 1648  
)  
Appln. No.: 09/988,213 ) Examiner: Parkin, J.  
)  
Filed: November 19, 2001 )  
)  
For: Nucleic Acids Containing the )  
Human Immunodeficiency Virus )  
Type 2 (HIV-2) Pol Gene And A )  
Method for Producing a Polypeptide )  
Encoded By The Nucleic Acids )  
(Amended Title) )  
)  
)  
)  
)

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS**

This paper is filed in response to the December 26, 2001, Notice to File  
Corrected Application Papers.

**IN THE DRAWINGS:**

Applicants submit new drawings (5 sheets including Figures 1A, 1B, 2A, 2B, 2C,  
2D, 3A, 3B, 4A, 4B and 5) in compliance with 37 C.F.R. §1.84 subject to approval by the  
Examiner. Applicants request that the Office enter these drawings into this application.

**SEQUENCE LISTING:**

Applicants submit that this application does not need to comply with the Sequence Rules because its effective U.S. filing date is January 16, 1987, the filing date of Appln. No. 07/003,764 (now U.S. Patent 5,051,496). The Sequence Rules 37 C.F.R. §§ 1.821-1.825 are not effective for applications whose effective U.S. filing dates are prior to October 1, 1990. Accordingly, no sequence listing is required.

If there is any fee due in connection with the filing of this response, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: February 25, 2002


By: Rebecca M. McNeill  
Rebecca M. McNeill  
Reg. No. 43,796

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com



UNITED STATES PATENT AND TRADEMARK OFFICE



COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/988,213	11/19/2001	Marc Alizon	3495.0050-16

CONFIRMATION NO. 8195

22852  
FINNEGAN, HENDERSON, FARABOW, GARRETT &  
DUNNER LLP  
1300 I STREET, NW  
WASHINGTON, DC 20005

**FORMALITIES LETTER**



\*OC000000007229805\*

Date Mailed: 12/26/2001

**NOTICE TO FILE CORRECTED APPLICATION PAPERS**

***Filing Date Granted***

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
  - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. ( 5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.


**For questions regarding compliance to these requirements, please contact:**

- **For Rules Interpretation, call (703) 308-4216**

- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

---

*A copy of this notice MUST be returned with the reply.*

  
\_\_\_\_\_  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE